These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18320691)

  • 1. Anti-HIV agents. A trial of Kaletra monotherapy.
    TreatmentUpdate; 2008 Jan; 20(1):2-3. PubMed ID: 18320691
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 5. Kaletra versus nelfinavir.
    TreatmentUpdate; 2001; 12(12):8-10. PubMed ID: 11570097
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 7. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 9. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 10. Kaletra goes it alone.
    Huff B
    GMHC Treat Issues; 2003 Sep; 17(9):11. PubMed ID: 14672062
    [No Abstract]   [Full Text] [Related]  

  • 11. CASTLE study showed similar efficacy.
    AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342
    [No Abstract]   [Full Text] [Related]  

  • 12. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions. Kaletra and ezetimibe.
    TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug interactions. Coming soon--a new formulation of Kaletra.
    TreatmentUpdate; 2006; 18(3):7. PubMed ID: 17209241
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV agents. Atazanavir vs. Kaletra.
    TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
    Pulido F; Delgado R; Pérez-Valero I; González-García J; Miralles P; Arranz A; Hernando A; Arribas JR
    J Antimicrob Chemother; 2008 Jun; 61(6):1359-61. PubMed ID: 18343802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaletra approved in Canada.
    TreatmentUpdate; 2001; 12(11):1-2. PubMed ID: 11570069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
    TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
    [No Abstract]   [Full Text] [Related]  

  • 20. [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
    Valencia-Ortega ME; Moreno-Celda V
    Enferm Infecc Microbiol Clin; 2008 Dec; 26(10):671-2. PubMed ID: 19100200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.